ORIC PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
ORIC PHARMACEUTICALS, INC. (ORIC) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$27.19 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-23
- ORIC PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$27.19M.
- ORIC PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$26.85M.
- ORIC PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$21.15M.
- ORIC PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$18.71M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$27.19M 10-K · filed 2026-02-23 |
| 2024-12-31 | -$26.85M 10-K · filed 2026-02-23 |
| 2023-12-31 | -$21.15M 10-K · filed 2025-02-18 |
| 2022-12-31 | -$18.71M 10-K · filed 2024-03-11 |
| 2021-12-31 | -$16.53M 10-K · filed 2023-03-16 |
| 2020-12-31 | -$15.48M 10-K · filed 2022-03-21 |
| 2019-12-31 | -$5.65M 10-K · filed 2022-03-21 |
| 2018-12-31 | -$4.49M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |